Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Financing Activities (2018 - 2025)

UroGen Pharma (URGN) has disclosed Cash from Financing Activities for 8 consecutive years, with $31.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 44007.04% year-over-year to $31.3 million, compared with a TTM value of $39.9 million through Dec 2025, down 79.49%, and an annual FY2025 reading of $39.9 million, down 79.49% over the prior year.
  • Cash from Financing Activities was $31.3 million for Q4 2025 at UroGen Pharma, up from $8.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $116.1 million in Q3 2023 and bottomed at -$168000.0 in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $26.0 million, with a median of $886000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities plummeted 375.41% in 2021, then soared 1768450.0% in 2022.
  • Year by year, Cash from Financing Activities stood at -$32000.0 in 2021, then soared by 79375.0% to $25.4 million in 2022, then crashed by 99.84% to $40000.0 in 2023, then skyrocketed by 77.5% to $71000.0 in 2024, then skyrocketed by 44007.04% to $31.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for URGN at $31.3 million in Q4 2025, $8.3 million in Q3 2025, and $296000.0 in Q2 2025.